Terms: = Leukemia AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990 AND Treatment
6 results:
1. STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation.
Kim D; Park G; Huuhtanen J; Ghimire B; Rajala H; Moriggl R; Chan WC; Kankainen M; Myllymäki M; Mustjoki S
Leukemia; 2021 Dec; 35(12):3430-3443. PubMed ID: 34075200
[TBL] [Abstract] [Full Text] [Related]
2. MYC as a target for cancer treatment.
Duffy MJ; O'Grady S; Tang M; Crown J
Cancer Treat Rev; 2021 Mar; 94():102154. PubMed ID: 33524794
[TBL] [Abstract] [Full Text] [Related]
3. Multiple primary non-breast tumors in breast cancer survivors.
Corso G; Veronesi P; Santomauro GI; Maisonneuve P; Morigi C; Peruzzotti G; Intra M; Sacchini V; Galimberti V
J Cancer Res Clin Oncol; 2018 May; 144(5):979-986. PubMed ID: 29502170
[TBL] [Abstract] [Full Text] [Related]
4. Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.
Schick M; Habringer S; Nilsson JA; Keller U
Br J Haematol; 2017 Dec; 179(5):724-738. PubMed ID: 29171017
[TBL] [Abstract] [Full Text] [Related]
5. Genetics of pleiotropic effects of dexamethasone.
Ramsey LB; Pounds S; Cheng C; Cao X; Yang W; Smith C; Karol SE; Liu C; Panetta JC; Inaba H; Rubnitz JE; Metzger ML; Ribeiro RC; Sandlund JT; Jeha S; Pui CH; Evans WE; Relling MV
Pharmacogenet Genomics; 2017 Aug; 27(8):294-302. PubMed ID: 28628558
[TBL] [Abstract] [Full Text] [Related]
6. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Zhong L; Shen H; Huang C; Jing H; Cao D
Toxicol Appl Pharmacol; 2011 Aug; 255(1):40-7. PubMed ID: 21640744
[TBL] [Abstract] [Full Text] [Related]
